As of today (2026-06-30), the Forward Annual Dividend Yield of Sarepta Therapeutics is 0.00%.
As of today (2026-06-30), the Trailing Annual Dividend Yield of Sarepta Therapeutics is 0.00%.
LTS:0L35's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.52 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Sarepta Therapeutics Forward Dividend Yield % Related Terms
LTS:0L35 vs ZYME, BCAX, INVA: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Sarepta Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sarepta Therapeutics Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Sarepta Therapeutics's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Sarepta Therapeutics (LTS:0L35) has a Forward Dividend Yield % of 0.00% as of Jun. 30, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Sarepta Therapeutics and its competitors. According to the industry distribution chart, Sarepta Therapeutics ranks #999999 out of 145 companies in the Biotechnology industry.
Is Sarepta Therapeutics' Forward Dividend Yield % too high?
Sarepta Therapeutics' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Sarepta Therapeutics ranks #999999 out of 145 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sarepta Therapeutics has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Forward Dividend Yield % compare to ZYME and BCAX?
According to the Biotechnology industry distribution chart, Sarepta Therapeutics ranks #999999 out of 145 companies for Forward Dividend Yield %. This places Sarepta Therapeutics in the lower half of its industry. The industry median Forward Dividend Yield % is 1.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.52, based on 145 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Sarepta Therapeutics and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sarepta Therapeutics's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (LTS:0L35) is currently considered Possible Value Trap. The stock's GF Value™ is $134.83, compared to a current price of $17.11 — trading 87.3% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Sarepta Therapeutics' overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Sarepta Therapeutics (LTS:0L35), the current Forward Dividend Yield % is 0.00% as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sarepta Therapeutics (LTS:0L35) Overvalued in 2026?
Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued.
The current stock price of $17.11 is trading 87.3% below its estimated GF Value™ of $134.83.
GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.
Key valuation signals for LTS:0L35:
Forward Dividend Yield %: 0.00%
GF Value™: $134.83 vs. price of $17.11 (87.3% below fair value)
No single metric tells the full story. See the LTS:0L35 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
50GF Score
Get the complete analysis for LTS:0L35
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0L35 has been successfully added to your 